e-learning
resources
Stockholm 2007
Monday 17.09.2007
Antibiotic treatment in community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
R. Anastasova, O. Georgiev, D. Petrova (Sofia, Bulgaria)
Source:
Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Session:
Antibiotic treatment in community-acquired pneumonia
Session type:
Electronic Poster Discussion
Number:
1880
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Anastasova, O. Georgiev, D. Petrova (Sofia, Bulgaria). Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin. Eur Respir J 2007; 30: Suppl. 51, 1880
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia
Source: Eur Respir J 2007; 30: 1234-1235
Year: 2007
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 135-143
Year: 2003
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to
legionella pneumophila
Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence
Year: 2004
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004
Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
The efficiency of levofloxacin in the therapy of community acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 5s
Year: 2006
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept